Waller C F, Bertz H, Wenger M K, Fetscher S, Hardung M, Engelhardt M, Behringer D, Lange W, Mertelsmann R, Finke J
Department of Haematology/Oncology, University Medical Center, Freiburg, Germany.
Bone Marrow Transplant. 1996 Aug;18(2):279-83.
Mobilization of PBPC was investigated in 19 healthy matched sibling donors using two different rhG-CSF regimens. Five donors (median age 39 years, range 17 to 57 years) received 10 micrograms rhG-CSF/kg bw once daily subcutaneously (s.c.), while 14 donors (median age 34 years, range 19 to 56 years) were treated with 10-12 micrograms rhG-CSF/kg bw twice daily s.c.. Leukapheresis was started on day 4 of rhG-CSF administration. Cytokine priming as well as collection of PBPCs were well tolerated. Application of twice daily rhG-CSF resulted in a higher yield of CD34+ cells in leukapheresis products than injection of once daily rhG-CSF. This high-dose twice daily rhG-CSF regimen is well tolerated and results in reliably high numbers of progenitor cells in the leukapheresis product in healthy donors, therefore collection as well as subsequent selection has been facilitated.
使用两种不同的重组人粒细胞集落刺激因子（rhG-CSF）方案，对19名健康匹配的同胞供者进行了外周血造血干细胞（PBPC）动员研究。5名供者（中位年龄39岁，范围17至57岁）每天皮下注射一次10微克rhG-CSF/千克体重，而14名供者（中位年龄34岁，范围19至56岁）每天皮下注射两次10 - 12微克rhG-CSF/千克体重。在rhG-CSF给药第4天开始进行白细胞单采。细胞因子启动以及PBPC采集耐受性良好。与每日注射一次rhG-CSF相比，每日注射两次rhG-CSF使白细胞单采产品中CD34+细胞产量更高。这种高剂量每日两次rhG-CSF方案耐受性良好，能使健康供者白细胞单采产品中祖细胞数量可靠地增加，因此便于采集及后续筛选。
